• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form 144/A filed by Monopar Therapeutics Inc.

    7/10/26 6:01:56 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MNPR alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144/A

    144/A: Filer Information

    Filer CIK
    0001207790
    Filer CCC
    XXXXXXXX
    Previous Accession Number Of The Filing
    0001628280-26-047461
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144/A: Issuer Information

    Name of Issuer
    Monopar Therapeutics Inc.
    SEC File Number
    Address of Issuer
    1000 Skokie Blvd
    Suite 350
    Wilmette
    ILLINOIS
    60091
    Phone
    847-388-0349
    Name of Person for Whose Account the Securities are To Be Sold
    Arthur Klausner
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Former Board Member

    144/A: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common Stock
    MLPFS
    One Bryant Park 40th fl
    New York � NY � 10036
    5000476967007/08/2026
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144/A: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common Stock12/31/2023Restricted Stock Unit VestingArthur KlausnerCheckbox not checked50607/08/2026Granted as part of issuer equity compensation plan.
    Common Stock09/30/2023Restricted Stock Unit VestingArthur KlausnerCheckbox not checked50707/08/2026Granted as part of issuer equity compensation plan.
    Common Stock06/30/2023Restricted Stock Unit VestingArthur KlausnerCheckbox not checked50707/08/2026Granted as part of issuer equity compensation plan.
    Common Stock03/31/2023Restricted Stock Unit VestingArthur KlausnerCheckbox not checked50707/08/2026Granted as part of issuer equity compensation plan.
    Common Stock12/31/2022Restricted Stock Unit VestingArthur KlausnerCheckbox not checked57107/08/2026Granted as part of issuer equity compensation plan.
    Common Stock09/30/2022Restricted Stock unit vestingArthur KlausnerCheckbox not checked57207/08/2026Granted as part of issuer equity compensation plan.
    Common Stock06/30/2022Restricted stock unit vestingArthur KlausnerCheckbox not checked57207/08/2026Granted as part of issuer equity compensation plan
    Common Stock03/31/2022Restricted stock unit vestingArthur KlausnerCheckbox not checked57207/08/2026Granted as part of issuer equity compensation plan
    Common Stock03/31/2021Restricted stock unit vestingArthur KlausnerCheckbox not checked15007/08/2026Granted as part of issuer equity compensation plan
    Common Stock06/30/2021Restricted stock unit vestingArthur KlausnerCheckbox not checked15007/08/2026Granted as part of issuer equity compensation plan
    Common Stock09/30/2021Restricted stock unit vestingArthur KlausnerCheckbox not checked15007/08/2026Granted as part of issuer equity compensation plan
    Common Stock12/31/2021Restricted stock unit vestingArthur KlausnerCheckbox not checked15107/08/2026Granted as part of issuer equity compensation plan
    Common Stock09/30/2020Restricted stock unit vestingArthur KlausnerCheckbox not checked2107/08/2026Granted as part of issuer equity compensation plan
    Common Stock12/31/2020Restricted stock unit vestingArthur KlausnerCheckbox not checked6407/08/2026Granted as part of issuer equity compensation plan

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144/A: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144/A: Remarks and Signature

    Remarks
    Date of Notice
    07/10/2026

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Arthur Klausner

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $MNPR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MNPR

    DatePrice TargetRatingAnalyst
    1/9/2026$115.00Overweight
    Morgan Stanley
    11/14/2025Strong Buy → Outperform
    Raymond James
    11/10/2025$115.00Outperform
    Leerink Partners
    10/13/2025$125.00Overweight
    Barclays
    9/9/2025$87.00Buy
    BTIG Research
    9/3/2025$77.00Outperform
    Oppenheimer
    9/3/2025$80.00Strong Buy
    Raymond James
    8/26/2025$70.00Buy
    H.C. Wainwright
    More analyst ratings

    $MNPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley initiated coverage on Monopar Therapeutics with a new price target

    Morgan Stanley initiated coverage of Monopar Therapeutics with a rating of Overweight and set a new price target of $115.00

    1/9/26 9:05:54 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Monopar Therapeutics downgraded by Raymond James

    Raymond James downgraded Monopar Therapeutics from Strong Buy to Outperform

    11/14/25 9:54:47 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Monopar Therapeutics with a new price target

    Leerink Partners initiated coverage of Monopar Therapeutics with a rating of Outperform and set a new price target of $115.00

    11/10/25 8:46:42 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Vu Quan Anh bought $104,925 worth of shares (1,500 units at $69.95) (SEC Form 4)

    4 - Monopar Therapeutics (0001645469) (Issuer)

    12/29/25 12:15:31 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Radhakrishnan Karthik bought $25,188 worth of shares (1,550 units at $16.25) (SEC Form 4)

    4 - Monopar Therapeutics (0001645469) (Issuer)

    10/30/24 4:17:28 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Cittadine Andrew bought $25,574 worth of shares (32,508 units at $0.79), increasing direct ownership by 21% to 186,132 units (SEC Form 4)

    4 - Monopar Therapeutics (0001645469) (Issuer)

    6/21/24 5:16:51 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNPR
    SEC Filings

    View All

    Amendment: SEC Form 144/A filed by Monopar Therapeutics Inc.

    144/A - Monopar Therapeutics (0001645469) (Subject)

    7/10/26 6:01:56 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Monopar Therapeutics Inc.

    144 - Monopar Therapeutics (0001645469) (Subject)

    7/7/26 2:28:59 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Monopar Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Monopar Therapeutics (0001645469) (Filer)

    6/30/26 8:00:16 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team

    WILMETTE, Ill., July 20, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the addition of seasoned commercial leaders to support the anticipated launch of the Company’s first commercial product, ALXN1840, pending U.S. Food and Drug Administration (FDA) approval. Nicole Sweeny, former Chief Commercial Officer of KalVista Pharmaceuticals, was elected to the Board of Directors at the Company’s Annual Meeting of Stockholders on June 22, 2026. In addition, Monopar has appointed Sharon Funk as Senior Vice President, Sales

    7/20/26 8:00:00 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease

    WILMETTE, Ill., June 30, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to ALXN1840 (tiomolibdate choline, TMC), the Company’s late-stage candidate for the treatment of Wilson disease. The FDA grants RPD designation to therapies intended to treat serious or life-threatening diseases that primarily affect children from birth to 18 years of age. The designation provides the Company with the potential at the time of

    6/30/26 8:00:00 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease

    WILMETTE, Ill., June 26, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that new analyses from the Phase 3 FoCus randomized controlled clinical trial of ALXN1840 (tiomolibdate choline, TMC) will be presented at the 12th Congress of the European Academy of Neurology (EAN 2026), June 27–30, 2026, in Geneva, Switzerland. These analyses build upon the previously reported Phase 3 FoCus results demonstrating ALXN1840 met its primary endpoint of superior copper mobilization versus standard of care. In an encore poster p

    6/26/26 4:05:00 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Vu Quan Anh converted options into 1,228 shares and covered exercise/tax liability with 507 shares, increasing direct ownership by 48% to 2,221 units (SEC Form 4) (for withholding tax)

    4 - Monopar Therapeutics (0001645469) (Issuer)

    7/2/26 7:38:27 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Robinson Chandler converted options into 12,873 shares and covered exercise/tax liability with 4,084 shares, increasing direct ownership by 10% to 99,267 units (SEC Form 4) to satisfy withholding obligation

    4 - Monopar Therapeutics (0001645469) (Issuer)

    7/2/26 7:38:00 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Cittadine Andrew converted options into 5,254 shares and covered exercise/tax liability with 2,309 shares, increasing direct ownership by 6% to 55,614 units (SEC Form 4) to satisfy tax liability

    4 - Monopar Therapeutics (0001645469) (Issuer)

    7/2/26 7:37:33 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNPR
    Leadership Updates

    Live Leadership Updates

    View All

    Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team

    WILMETTE, Ill., July 20, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the addition of seasoned commercial leaders to support the anticipated launch of the Company’s first commercial product, ALXN1840, pending U.S. Food and Drug Administration (FDA) approval. Nicole Sweeny, former Chief Commercial Officer of KalVista Pharmaceuticals, was elected to the Board of Directors at the Company’s Annual Meeting of Stockholders on June 22, 2026. In addition, Monopar has appointed Sharon Funk as Senior Vice President, Sales

    7/20/26 8:00:00 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer

    WILMETTE, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR) ("Monopar" or the "Company"), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer, effective immediately. In this newly created executive role, Ms. Rodriguez will lead the Company's commercial strategy and infrastructure build-out as Monopar prepares for the planned submission of a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") in the first half of 2026 for ALXN1840, its late-stage investigational therapy for Wilson d

    3/2/26 8:00:00 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics

    Monopar's pipeline includes clinical-stage radiopharmaceuticals targeting advanced solid tumors and late-stage ALXN1840, a treatment for Wilson Disease  NORTH CHICAGO, Ill., Jan. 23, 2025 /PRNewswire/ -- Rosalind Franklin University of Medicine and Science announced that Monopar Therapeutics is the latest biotech company to join the Helix 51 biomedical incubator community. Monopar, a clinical-stage biotechnology firm, is developing personalized and precise radiopharmaceuticals to diagnose and treat aggressive cancers, and will utilize the labs and other resources in Helix 51 t

    1/23/25 1:10:00 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Monopar Therapeutics Inc.

    SC 13D/A - Monopar Therapeutics (0001645469) (Subject)

    12/17/24 5:01:42 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Monopar Therapeutics Inc.

    SC 13G - Monopar Therapeutics (0001645469) (Subject)

    11/6/24 3:13:14 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Monopar Therapeutics Inc.

    SC 13G - Monopar Therapeutics (0001645469) (Subject)

    10/31/24 4:17:57 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNPR
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at Monopar Therapeutics Inc. on Jun 21 Indicate?

    Monopar Therapeutics Inc. has recently seen notable insider activity, with Chief Operating Officer Cittadine Andrew purchasing $25,574 worth of shares on June 21st, 2024. This purchase, comprising 32,508 units at $0.79, increased Cittadine's direct ownership by 21% to 186,132 units as reported in the SEC Form 4. When analyzing this transaction alongside other recent insider activities within the company, interesting patterns and trends start to emerge. Looking back, Cittadine Andrew has been consistently adding to his position in Monopar Therapeutics Inc. over the past few months, showcasing a strong conviction in the company's future prospects. On May 31st, Cittadine Andrew made a substan

    6/22/24 8:00:00 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care